Tissue processor employs gamma-sterilization technology

DEC. 15–KENNESAW, Ga.–CryoLife, Inc., a human tissue processing and bio-surgical device company, announced today that it has licensed a patented technology from Clearant, Inc. designed to inactivate microorganisms, including pathogens, from tissue obtained from human donors.

CryoLife plans to further develop and employ this technology in processing human orthopaedic tissue primarily used in the repair of sports injuries.

This technology is based on gamma irradiation and is designed to substantially reduce microbial contamination and other pathogens, while maintaining tissue integrity.

“We are pleased to finalize this agreement with Clearant, which gives us access to their unique technology for processing human orthopedic tissue allografts. Our ultimate goal is to provide patients with sterile orthopaedic tissue,” said Steven G. Anderson, President and CEO of CryoLife.

Since the Company was founded in 1984, more than 100,000 patients have received CryoLife processed tissues in cardiac, vascular, and orthopaedic reconstruction surgical procedures.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.